WallStSmart

Ekso Bionics Holdings Inc (EKSO)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 222042% more annual revenue ($28.43B vs $12.80M). MDLN leads profitability with a 4.1% profit margin vs -91.4%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

EKSO

Avoid

20

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -13.03

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EKSO.

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.67

$24.25 discount

UndervaluedFair: $66.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EKSO0 strengths · Avg: 0/10

No standout strengths identified

MDLN0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

EKSO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$37.56M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-107.6%2/10

ROE of -107.6% — below average capital efficiency

Revenue GrowthGrowth
-38.3%2/10

Revenue declined 38.3%

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : EKSO

EKSO has a balanced fundamental profile.

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bear Case : EKSO

The primary concerns for EKSO are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

EKSO profiles as a turnaround stock while MDLN is a value play — different risk/reward profiles.

MDLN is growing revenue faster at 14.8% — sustainability is the question.

EKSO generates stronger free cash flow (-4M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 20/100) and 14.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ekso Bionics Holdings Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company is headquartered in Richmond, California.

Visit Website →

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?